Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
103 participants
INTERVENTIONAL
2012-07-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CKD-828 Primary Hypertension Trial(Dose-selection)
NCT01128322
CKD-828 S-Amlodipine Non-Responder Trial
NCT01501253
CKD-828 Telmisartan Non-Responder Trial
NCT01426100
CKD-828 (80/5mg) Pharmacokinetic Study
NCT02358824
CKD-828 (80/5mg) Pharmacokinetic Study
NCT02250833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* This study is consist of placebo run-in period(2 weeks\_single blind) and treatment period(10 weeks\_double blind.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CKD-828 2.5/40, 2.5/80, 5/80mg
CKD-828 2.5/40mg
* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.
* With the others investigation product placebo 4 tabs QD 2 weeks.
CKD-828 5/40mg
* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.
* With the others investigation product placebo 4 tabs QD 2 weeks.
CKD-828 5/80mg
* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.
* With the others investigation product placebo 4 tabs QD 6 weeks.
S-Amlodipine 2.5, 5mg
S-amlodipine 2.5mg
* S-amlodipine 2.5mg QD 4 weeks
* With the others investigation product placebo 4 tabs QD 4 weeks.
S-amlodipine 5mg
* S-amlodipine 2.5mg QD 6weeks
* With the others investigation product placebo 4 tabs QD 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-828 2.5/40mg
* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.
* With the others investigation product placebo 4 tabs QD 2 weeks.
CKD-828 5/40mg
* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.
* With the others investigation product placebo 4 tabs QD 2 weeks.
CKD-828 5/80mg
* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.
* With the others investigation product placebo 4 tabs QD 6 weeks.
S-amlodipine 2.5mg
* S-amlodipine 2.5mg QD 4 weeks
* With the others investigation product placebo 4 tabs QD 4 weeks.
S-amlodipine 5mg
* S-amlodipine 2.5mg QD 6weeks
* With the others investigation product placebo 4 tabs QD 6 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at the screening visit
* antihypertensive drugs not taking: 160mmHg ≤ sitSBP \< 200mmHg
* antihypertensive drugs taking: 140mmHg ≤ sitSBP \< 180mmHg
* at the randomization visit(160mmHg ≤ sitSBP \< 200mmHg)
* willing and able to provide written informed consent
Exclusion Criteria
* for the past four weeks based on beginning of administration, patients took over four antihypertensive drugs
* known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
* has severe heart disease(Heart failure NYHA functional class 3, 4), ischaemic heart diseasesstatus need to treatment, myocardiopathy, Valve disease, arrhythmia and so on and operated Coronary angioplasty
* has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
* Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) \> 8%)
* known severe or malignant retinopathy
* defined by the following laboratory parameters:
* hepatic dysfunction(AST/ALT \> UNL X 3)
* renal dysfunction(serum creatinine \> UNL X 1.5)
* hypopotassemia(K \< 3.0mmol/L) or hyperpotassemia (K\>5.5 mmol/L)
* acute or chronic inflammatory status need to treatment
* need to additional antihypertensive drugs during the study
* need to concomitant medications known to affect blood pressure during the study
* history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
* known hypersensitivity related to either study drug
* history of drug or alcohol dependency within 6 months
* any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding)
* administration of other study drugs within 4weeks prior to randomization
* premenopausal women(last menstruation \< 1year) not using adequate contraception, pregnant or breast-feeding
* history of malignancy including leukemia and lymphoma within the past 5 years
* in investigator's judgment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tae-hoon An, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Gachon University Gil Medical Center
Eun-joo Jo, Ph.D
Role: PRINCIPAL_INVESTIGATOR
The Catholic university of Korea St. Paul's Hospitial
Jong-jin Kim, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Kyung Hee university Hosipital at Gangdong
Jang-ho Bae, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Konyang University Hosipital
Chang-kyu Park, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Young-dae Kim, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Dong-A University
Chul-ho Kim, Ph.D
Role: STUDY_CHAIR
Seoul National University Bundang Hospital
Sae-Joong Lim, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Gangnam Severance Hospital
Uk-Bum Phyun, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Ewha Women University Mokdong Hospital
Gyu-Rok Han, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Kangdong Sacred Heart Hospital
Sang Hyun Kim, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Boramae Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul national university Bundang Hospital
Bundang-gu, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
130HT11P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.